Shanghai Pharmaceuticals Holding's (HKG:2607, SHA:601607) subsidiary, Shanghai Xinyi Wanxiang Pharmaceutical, received approval from China's National Medical Products Administration to market its raw drug ingredient, Alfacalcidol, according to an Oct. 1 disclosure on the Shanghai Stock Exchange.
The Chinese pharmaceutical company invested 4.4 million yuan into the research and development of the drug, which is mainly used to treat calcium metabolism disorders.
Price (HKD): $14.58, Change: $+0.48, Percent Change: +3.40%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments